Amgen Inc. (AMGN) Stake Decreased by Whittier Trust Co.
Whittier Trust Co. cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.2% during the second quarter, Holdings Channel reports. The firm owned 60,305 shares of the medical research company’s stock after selling 148 shares during the period. Whittier Trust Co.’s holdings in Amgen were worth $9,176,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Tiemann Investment Advisors LLC purchased a new stake in Amgen during the first quarter valued at $226,000. Badgley Phelps & Bell Inc. raised its stake in Amgen by 12.1% in the first quarter. Badgley Phelps & Bell Inc. now owns 28,150 shares of the medical research company’s stock valued at $4,221,000 after buying an additional 3,048 shares during the last quarter. Compton Capital Management Inc. RI raised its stake in Amgen by 1.5% in the first quarter. Compton Capital Management Inc. RI now owns 6,060 shares of the medical research company’s stock valued at $909,000 after buying an additional 90 shares during the last quarter. Northern Oak Wealth Management Inc. raised its stake in Amgen by 8.5% in the first quarter. Northern Oak Wealth Management Inc. now owns 33,774 shares of the medical research company’s stock valued at $5,064,000 after buying an additional 2,640 shares during the last quarter. Finally, Bowling Portfolio Management LLC raised its stake in Amgen by 46.5% in the first quarter. Bowling Portfolio Management LLC now owns 61,778 shares of the medical research company’s stock valued at $9,262,000 after buying an additional 19,600 shares during the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) traded down 1.45% during midday trading on Friday, reaching $161.90. The company’s stock had a trading volume of 2,817,469 shares. Amgen Inc. has a one year low of $139.02 and a one year high of $176.85. The stock has a market cap of $121.16 billion, a PE ratio of 16.57 and a beta of 0.94. The firm has a 50-day moving average of $169.59 and a 200-day moving average of $162.28.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business earned $5.69 billion during the quarter, compared to the consensus estimate of $5.58 billion. During the same quarter in the prior year, the company posted $2.57 earnings per share. Amgen’s revenue was up 5.9% compared to the same quarter last year. On average, analysts forecast that Amgen Inc. will post $11.35 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 8th. Investors of record on Wednesday, November 16th will be issued a dividend of $1.00 per share. This represents a $4.00 annualized dividend and a yield of 2.47%. Amgen’s dividend payout ratio (DPR) is currently 40.90%.
AMGN has been the topic of several analyst reports. Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a report on Sunday, June 26th. Sanford C. Bernstein initiated coverage on shares of Amgen in a report on Wednesday, June 29th. They issued a “market perform” rating and a $161.00 target price on the stock. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $166.00 target price on the stock in a report on Wednesday, June 29th. Morgan Stanley reaffirmed an “overweight” rating on shares of Amgen in a report on Wednesday, June 29th. Finally, Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Amgen in a research report on Wednesday, June 29th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $184.94.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.